Received Jan 22, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
sinuses and throat to fill up with mucus; sinuses and throat to fill up with mucus; This non-serious case was reported by a consumer via call center representative and described the occurrence of sinus congestion in a female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (1st dose of Shingrix). On 12-JAN-2026, the patient received the 2nd dose of Shingrix. In JAN-2026, an unknown time after receiving Shingrix, the patient experienced sinus congestion (Verbatim: sinuses and throat to fill up with mucus) and upper respiratory tract congestion (Verbatim: sinuses and throat to fill up with mucus). The outcome of the sinus congestion and upper respiratory tract congestion were not resolved. It was unknown if the reporter considered the sinus congestion and upper respiratory tract congestion to be related to Shingrix. It was unknown if the company considered the sinus congestion and upper respiratory tract congestion to be related to Shingrix. Additional Information: GSK receipt date: 16-JAN-2026 This case was reported by a patient via interactive digital media. Patient reported that her boyfriend, who also received the vaccine, experienced similar symptoms. According to the reporter, both individuals had been experiencing these symptoms for approximately three days and described them as very uncomfortable. The batch number was not provided. This case is linked to US2026AMR008412, for the different patients from same reporter.; Sender's Comments: US-GSK-US2026AMR008412:Same Reporter